利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.009 秒)

    Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori
    2.
    发明公开
    Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori 失效
    含有利福昔明-利福昔明和使用对于由幽门螺杆菌引起的胃消化不良的治疗药物组合物。

    公开(公告)号：EP0616808A1

    公开(公告)日：1994-09-28

    申请号：EP94104308.5

    申请日：1994-03-18

    申请人： ALFA WASSERMANN S.p.A.

    发明人： Ferrieri, Antonella ,  Rotini, Leone Gabriele

    IPC分类号： A61K31/44

    CPC分类号： A61K31/44

    摘要： This invention refers to the use of the rifamycin antibiotic known by the name of rifaximin (INN) and to pharmaceutical compositions containing it in the oral treatment of the forms of gastric dyspepsia caused by bacteria known as Helicobacter pylori.
    Rifaximin may be administered in any oral pharmaceutical form, particularly tablets, capsules, sugar coated tablets, granules and syrups containing from 200 to 2000 mg of active principle, at a daily dosage of between 400 and 2000 mg.

    摘要翻译： 本发明涉及使用由利福昔明（INN）的名称和在胃消化不良的通过被称为幽门螺杆菌细菌引起的形式口服治疗含有它的药物组合物的已知的利福霉素抗生素。 利福昔明可以以任何口服药物剂型，特别是片剂，胶囊，糖包衣片剂，颗粒剂和含从200到2000毫克活性成分糖浆给药，在400和2000之间的日剂量。